Browse the evidence

Participants with higher adherence scores for an overall low-carbohydrate diet (LCD) exhibited lower odds of hepatic steatosis (OR = 0.76, 95% CI: 0.61-0.96, p trend = 0.049).

Encouraging adherence to low-carbohydrate diets may reduce the risk of hepatic steatosis.

Replacing 5% of the energy from carbohydrates with total fat and protein is associated with lower steatosis prevalence (OR = 0.91, 95% CI: 0.83-0.99).

Modifying carbohydrate intake by increasing fat and protein may help lower the risk of hepatic steatosis.

For every pound of weight lost, there was a 0.02-point reduction on the HbA1C measured at the end of the RPM.

Practitioners can use weight loss as a target to help improve HbA1C levels in T2D patients.

Excess adiposity is associated with worse outcomes in breast cancer survivors.

Practitioners should consider addressing excess adiposity in breast cancer survivors to improve health outcomes.

Excess adiposity can be targeted to improve breast cancer outcomes.

Interventions aimed at reducing excess adiposity may enhance survivorship and quality of life for breast cancer survivors.

Tirzepatide-associated improvements in cardiometabolic risk factors are positively related to the degree of weight reduction.

Weight reduction through tirzepatide can lead to significant improvements in cardiometabolic health.

Improvements in triglycerides, HDL cholesterol, LDL cholesterol, and non-HDL cholesterol were primarily observed after weight reductions greater than 10%.

Targeting a weight reduction of over 10% may be necessary for significant improvements in lipid profiles.

The steepest improvements in cardiometabolic risk factors occurred between less than 5% and less than 20% weight reduction.

Practitioners should note that even modest weight loss can lead to significant health improvements, particularly within the 5-20% range.

A higher percentage of individuals consuming protein supplements with meals showed an increase in the ratio of lean mass to fat mass over time compared to those consuming between meals.

Encouraging protein consumption with meals may enhance body composition improvements.

Lifestyle modifications have shown to prevent the progression to type 2 diabetes mellitus.

Practitioners should emphasize lifestyle modifications for diabetes prevention.

Type of nutrient and food supplements are essential for a quicker recovery, in addition to their timing and dose.

Focus on specific nutrients and supplements, along with their timing, to enhance recovery.

Time-dependent increases were detected from baseline to week 8 for muscle thickness and strength.

Resistance training leads to significant improvements in muscle thickness and strength over 8 weeks.

SGLT-2 inhibitors and GLP-1 receptor agonists (GLP-1RAs) lead to a decline in body weight ranging from 1.5 to 5 kg.

Practitioners can consider SGLT-2 inhibitors and GLP-1RAs as effective options for weight loss in patients.

Obesity is a major risk factor for the development and progression of type 2 diabetes.

Addressing obesity is crucial for managing type 2 diabetes.

Tirzepatide increases insulin secretion, reduces glucagon release, decreases fasting and postprandial glucose levels, promotes satiety, decreases body weight, and delays gastric emptying.

Tirzepatide can help manage blood sugar levels and weight in patients with type 2 diabetes.

The proportion of participants meeting the criteria for diabetes remission increased from 8.8% at baseline to 32.4% at 24 months.

A structured dietary intervention may enhance the likelihood of diabetes remission in T2DM patients.

Bariatric interventions resulted in reductions in body mass index and hemoglobin A1c.

Bariatric surgery can lead to improvements in metabolic health markers.

The LLHR group showed greater strength endurance increases (65 % 1RM) of 8 repetitions (95 % CI (2, 14)).

Lighter load training can effectively improve strength endurance in middle and older adults.

Tirzepatide significantly reduces body mass index, waist circumference, blood pressure, and atherosclerotic cardiovascular disease risk.

Tirzepatide may improve overall cardiometabolic health in non-diabetic obese patients.

Modest weight loss of 2-3% of body weight is recommended to improve therapeutic durability and prevent beta-cell deterioration.

Encouraging patients to achieve modest weight loss can enhance their diabetes management.

A produce prescription program significantly improved HbA1c among low-income patients on Medicaid with poor glycemic control at baseline.

Implementing produce prescription programs may help improve glycemic control in low-income diabetic patients.

HbA1c at 6 months was significantly reduced in the intervention group compared to control.

The intervention may be effective in lowering HbA1c levels in similar patient populations.

Patients in the semaglutide group experienced greater weight loss compared to the control group (−8.2% vs. −4.6%; P <0.001).

Semaglutide may be effective for weight management in patients post-ablation.

Bariatric surgery effectively improves the management of obesity and inhibits the progression of multiple metabolic diseases.

Bariatric surgery should be considered as a viable option for managing obesity and related metabolic conditions.